EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

In-depth plasma proteomics reveals the dynamic changes and prognostic biomarkers for chimeric antigen receptor-glypican-3 T-cell therapy in patients with hepatocellular carcinoma

Xudong Zhu, Ziliang Yang, Bin Li, Zhou Tong, Junyi Yan, Lei Song, Xuanwen Bao, Libin Hong, Yuzhi Jin, Lina Meng, Lulu Liu, Xiaomeng Dai und 10 weitere

Gastroenterology Report · 11.01.2025 · 13

DOI: 10.1093/gastro/goaf100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastroenterology Report, online erschienen am 04.12.2025. Verfasst von Xudong Zhu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR) T-cell therapy has shown notable advancements in the treatment of solid tumors. Nevertheless, its effectiveness is limited to a small group of patients, highlighting the need for predictive biomarkers. This study aimed to investigate biomarkers associated with the efficacy of CAR-T therapy in hepatocellular carcinoma (HCC).

Methods

We prospectively collected plasma samples from 17 patients with HCC before and after they underwent CAR-glypican-3 (GPC3) T-cell therapy as part of three clinical trials. Plasma proteomic profiling was conducted by using liquid chromatography-mass spectrometry. We examined sequential plasma samples to evaluate the impact of CAR T-cell therapy on the systemic plasma proteome. Additionally, we compared the pretreatment plasma protein profiles between groups with and without clinical benefit (CB) to identify proteins linked to treatment efficacy. The Cox proportional hazard model was used to evaluate the relationship between plasma protein levels and survival outcomes.

Results

Among 5337 plasma proteins, 225 exhibited significant changes following CAR-GPC3 T-cell therapy. The CB group showed an increased expression in proteins related to the type I interferon signaling pathway, T-cell proliferation and activation, tumor necrosis factor production, and antigen processing and presentation. In addition, plasma proteins were significantly associated with survival outcomes, whereas no significant association was observed between clinical variables and prognosis.

Conclusions

Plasma proteomics not only captured CAR-GPC3-driven plasma microenvironment remodeling but also identified baseline proteins predictive of CB and survival, which were superior to clinical variables, thus constituting a candidate biomarker panel for HCC patient selection and response monitoring.

Schlagwörter

Stichwörter der Autor:innen

CAR T-cell therapyhepatocellular carcinomaprognosticproteomics

Autor:innen und Institutionen

  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
  • Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
  • CARsgen Therapeutics Co., Ltd., Shanghai, P. R. China.
  • Tianjin Key Laboratory of Clinical Multi-Omics, Tianjin, P. R. China.
  • National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
  • Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, Zhejiang, P. R. China.

ORCID-Profile: Zonghai Li, Tingbo Liang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhu, X., Yang, Z., Li, B., Tong, Z., Yan, J., Song, L., Bao, X., Hong, L., Jin, Y., Meng, L., Liu, L., Dai, X., Zhao, T., Wen, S., Qin, H., Jin, S., Zhao, P., Zheng, Y., Fang, W., …, & Liang, T. (2025). In-depth plasma proteomics reveals the dynamic changes and prognostic biomarkers for chimeric antigen receptor-glypican-3 T-cell therapy in patients with hepatocellular carcinoma. Gastroenterology Report, 13. https://doi.org/10.1093/gastro/goaf100

Vancouver

Zhu X, Yang Z, Li B, Tong Z, Yan J, Song L, et al. In-depth plasma proteomics reveals the dynamic changes and prognostic biomarkers for chimeric antigen receptor-glypican-3 T-cell therapy in patients with hepatocellular carcinoma. Gastroenterology Report. 2025;13. doi:10.1093/gastro/goaf100

BibTeX
@article{Zhu2025,
  author = {Zhu, Xudong and Yang, Ziliang and Li, Bin and Tong, Zhou and Yan, Junyi and Song, Lei and Bao, Xuanwen and Hong, Libin and Jin, Yuzhi and Meng, Lina and Liu, Lulu and Dai, Xiaomeng and Zhao, Tianyi and Wen, Shiting and Qin, Haokang and Jin, Sujie and Zhao, Peng and Zheng, Yi and Fang, Weijia and Li, Zonghai and Sun, Xuqi and Liang, Tingbo},
  title = {In-depth plasma proteomics reveals the dynamic changes and prognostic biomarkers for chimeric antigen receptor-glypican-3 T-cell therapy in patients with hepatocellular carcinoma},
  journal = {Gastroenterology Report},
  year = {2025},
  volume = {13},
  doi = {10.1093/gastro/goaf100}
}
Kostenlos starten →